Company intelligence / Profile preview

ERC Belgium

Isnes, Namur, Belgium

Ownership: Private
Employees: ~25
Development stage: Other

Overview

ERC is a clinical-stage biopharmaceutical company focused on developing personalized cell-based immunotherapies for brain cancer and other solid tumors. Its lead product, Gliovac (ERC1671), is a first-in-class immunotherapy that combines autologous and allogeneic tumor cells to trigger a comprehensive immune response against glioblastoma multiforme. The company's approach is designed to overcome the high heterogeneity of tumors by using a broad spectrum of tumor-associated antigens. ERC is headquartered in Belgium and maintains active clinical development programs in both Europe and the United States.

Therapeutic areas: Oncology
Modalities: Cell therapyVaccine
Industry: Biotech

Drug pipeline

1 asset

Sitoiganap

Partnerships

University of California, IrvineMedical University of Vienna

Beyond the preview

Go deeper on ERC Belgium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERC Belgium.

Explore the full profile